CL2008003378A1 - Compuestos derivados de 9,10-dioxo-2-antracen-carboxilico sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de condiciones que son influenciadas por citoquinas pro-inflamatorias de la familia il-1, particularmente enfermedades inflamatorias y autoinmunes. - Google Patents

Compuestos derivados de 9,10-dioxo-2-antracen-carboxilico sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de condiciones que son influenciadas por citoquinas pro-inflamatorias de la familia il-1, particularmente enfermedades inflamatorias y autoinmunes.

Info

Publication number
CL2008003378A1
CL2008003378A1 CL2008003378A CL2008003378A CL2008003378A1 CL 2008003378 A1 CL2008003378 A1 CL 2008003378A1 CL 2008003378 A CL2008003378 A CL 2008003378A CL 2008003378 A CL2008003378 A CL 2008003378A CL 2008003378 A1 CL2008003378 A1 CL 2008003378A1
Authority
CL
Chile
Prior art keywords
inflammatory
pro
influenced
family
pharmaceutical composition
Prior art date
Application number
CL2008003378A
Other languages
English (en)
Inventor
Carlino Alessandro Di Napoli Stefano
Original Assignee
Laboratoire Medidom S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39262809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003378(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoire Medidom S A filed Critical Laboratoire Medidom S A
Publication of CL2008003378A1 publication Critical patent/CL2008003378A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/57—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C07C309/60—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)

Abstract

COMPUESTOS QUE PUEDEN TENER ACTIVIDAD ANTI-INFLAMATORIA TIENEN LA FÓRMULA GENERAL ( I ) :  EN DONDE R1 , R2 , R3 SON CADA UNO INDEPENDIENTEMENTE H O UN GRUPO ALQUILO C1_4 O UN GRUPO ACILO C2-4, R4 Y R5 SON CADA UNO INDEPENDIENTEMENTE H O UN GRUPO DE LA FÓRMULA -SO 3R6 , EN DONDE R6 ES H O UN GRUPO ALQUILO C1_4 O UN GRUPO ACILO C2_4, CON LA CONDICIÓN DE QUE AL MENOS UNO DE R4 Y R5 ES UN GRUPO DE LA FÓRMULA —S0 3R6 , O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO. PROCEDIMIENTO DE PREPARACIÓN DE LOS COMPUESTOS; COMPOSICIÓN FARMACÉUTICA; Y SU USO EN EL TR AMIENTO DE CONDICIONES QUE SON INFLUENCIADAS POR CITOQUINAS PRO-INFLAMATORIAS DE LA FAMILIA IL-1, PARTICULARMENTE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES.
CL2008003378A 2007-11-16 2008-11-13 Compuestos derivados de 9,10-dioxo-2-antracen-carboxilico sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de condiciones que son influenciadas por citoquinas pro-inflamatorias de la familia il-1, particularmente enfermedades inflamatorias y autoinmunes. CL2008003378A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07022268A EP2060562A1 (en) 2007-11-16 2007-11-16 Dioxoanthracene sulphonate derivatives

Publications (1)

Publication Number Publication Date
CL2008003378A1 true CL2008003378A1 (es) 2011-04-01

Family

ID=39262809

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003378A CL2008003378A1 (es) 2007-11-16 2008-11-13 Compuestos derivados de 9,10-dioxo-2-antracen-carboxilico sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de condiciones que son influenciadas por citoquinas pro-inflamatorias de la familia il-1, particularmente enfermedades inflamatorias y autoinmunes.

Country Status (19)

Country Link
US (2) US8754128B2 (es)
EP (2) EP2060562A1 (es)
JP (1) JP5512532B2 (es)
KR (1) KR101527620B1 (es)
CN (1) CN101861301B (es)
AR (1) AR071255A1 (es)
AU (1) AU2008322341B2 (es)
BR (1) BRPI0819320B1 (es)
CA (1) CA2704630C (es)
CL (1) CL2008003378A1 (es)
CO (1) CO6270356A2 (es)
DK (1) DK2220036T3 (es)
ES (1) ES2400028T3 (es)
MX (1) MX2010004800A (es)
MY (1) MY153945A (es)
PT (1) PT2220036E (es)
RU (1) RU2482109C2 (es)
UA (1) UA99745C2 (es)
WO (1) WO2009063427A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120157391A1 (en) 2009-07-16 2012-06-21 Hirosaki University Proteoglycan-containing material
RU2592850C2 (ru) 2011-01-19 2016-07-27 Хиросаки Юниверсити Способ крупномасштабного получения протеогликана
EP2878302B1 (en) * 2012-07-25 2019-11-27 Hirosaki University Composition for preventing or treating osteoarthrosis
CN103110617A (zh) * 2013-03-22 2013-05-22 中国人民解放军肾脏病研究所 一种双醋瑞因在制备治疗糖尿病肾病药物中的用途
US20160252954A1 (en) * 2015-02-27 2016-09-01 Microsoft Technology Licensing, Llc Control apparatus
WO2017123672A1 (en) * 2016-01-12 2017-07-20 Lawrence Chan Combination treatment for inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
GB9103075D0 (en) * 1991-02-13 1991-03-27 Washington Odur Ayuko Trinitrobenzene derivatives and their therapeutic use
DE4120990C2 (de) 1991-06-25 1995-07-27 Madaus Ag Verfahren zur Herstellung von Diacetylrhein
AU666704B2 (en) * 1992-02-28 1996-02-22 Lilly Industries Limited Anthraquinone compounds and pharmaceutical compositions containing them
IT1264545B1 (it) 1993-07-30 1996-10-02 Medidom Lab Procedimento per la preparazione della diacereina
FR2757397B1 (fr) * 1996-12-23 1999-03-05 Mazal Pharma Composition pharmaceutique a base de rheine ou de diacerheine a biodisponibilite amelioree
AR026801A1 (es) * 2000-01-12 2003-02-26 Medidom Lab Sustancias para uso en el tratamiento de la psoriasis
AU2001277068A1 (en) 2000-07-24 2002-02-05 Cbite, Inc. Disposable articulator having at least one continuous opening for acceptance of stabilization means
US6610750B1 (en) 2000-09-15 2003-08-26 Laboratoires Negma Treatment of osteoarthritis
US20020128317A1 (en) 2001-01-23 2002-09-12 Laboratories Negma Treatment of pathological conditions characterized by an increased IL-1 level
AU2002305926A1 (en) * 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
RU2246485C1 (ru) * 2003-11-04 2005-02-20 Государственное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ГОУВПО "ИГХТУ") 2,3-дикарбокси-6-сульфоантрахинон
RU2280027C1 (ru) * 2005-03-18 2006-07-20 Государственное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ГОУВПО "ИГХТУ") 2,3-дикарбокси-5,8-диметокси-6-сульфоантрахинон

Also Published As

Publication number Publication date
RU2010124422A (ru) 2011-12-27
EP2220036A1 (en) 2010-08-25
US8754128B2 (en) 2014-06-17
US20150011636A1 (en) 2015-01-08
PT2220036E (pt) 2013-03-05
MY153945A (en) 2015-04-15
EP2220036B1 (en) 2012-12-26
AU2008322341A1 (en) 2009-05-22
ES2400028T3 (es) 2013-04-05
HK1147738A1 (en) 2011-08-19
WO2009063427A1 (en) 2009-05-22
CN101861301B (zh) 2013-05-29
EP2060562A1 (en) 2009-05-20
KR20100097162A (ko) 2010-09-02
KR101527620B1 (ko) 2015-06-09
AR071255A1 (es) 2010-06-09
BRPI0819320B1 (pt) 2021-11-09
JP2011503170A (ja) 2011-01-27
UA99745C2 (en) 2012-09-25
CA2704630C (en) 2016-01-19
AU2008322341B2 (en) 2013-02-21
JP5512532B2 (ja) 2014-06-04
RU2482109C2 (ru) 2013-05-20
US20110054032A1 (en) 2011-03-03
MX2010004800A (es) 2010-05-20
DK2220036T3 (da) 2013-03-25
BRPI0819320A2 (pt) 2020-09-08
CO6270356A2 (es) 2011-04-20
CA2704630A1 (en) 2009-05-22
CN101861301A (zh) 2010-10-13

Similar Documents

Publication Publication Date Title
BR112012020557A2 (pt) formas cristalinas de sódio 4- {[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido [5,4-d] [2] benzazepin-2-il]-amino}-2 metoxibenzoato de sódio.
CL2008003378A1 (es) Compuestos derivados de 9,10-dioxo-2-antracen-carboxilico sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de condiciones que son influenciadas por citoquinas pro-inflamatorias de la familia il-1, particularmente enfermedades inflamatorias y autoinmunes.
EA200400162A1 (ru) N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения
ECSP045073A (es) Nuevos derivados de piperazina
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
CY1113872T1 (el) Ενωσεις imidazo[1,2-a]pyrazine για την θεραπεια μολυνσεων απο ιους οπως ηπατιτιδα
AR019626A1 (es) Antagonistas receptores y5 de neuropeptidos.
AR047529A1 (es) Compuestos de quinolina sustituidos
ECSP066456A (es) Inhibidores macrocíclicos de la serina proteasa ns3 del virus de la hepatitis c
EA201101243A1 (ru) 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств
CL2004000918A1 (es) Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
BRPI0515546A (pt) compostos para inflamação e usos imune-relacionados
BRPI0516825A (pt) inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
ATE543819T1 (de) Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
AR045901A1 (es) Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion,
AR088919A2 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y uso
EA201100942A1 (ru) Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
EA200500006A1 (ru) Лекарственное средство для лечения нейродегенеративных заболеваний
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
ATE552246T1 (de) Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
AR048573A1 (es) Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima